{
    "clinical_study": {
        "@rank": "58689", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Intervention Device: Rev-01"
        }, 
        "brief_summary": {
            "textblock": "The main objective of this study is to document that the thrombectomy catheter (Rev-01) is\n      effective and safe when used for revascularization in subjects with acute ischemic stroke\n      within 8 hours of symptom onset who are ineligible for treatment with IV t-PA, or in whom\n      treatment with IV t-PA has been ineffective."
        }, 
        "brief_title": "Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Onset of symptom is <= 8 hours prior to treatment with Rev-01\n\n          -  Treatment with IV t-PA is ineligible or ineffective\n\n          -  Occluded (presenting TICI score of 0 or 1) M1 or M2 of MCA, basilar or vertebral\n             artery, or intracranial segment of ICA, confirmed by angiography that it is\n             accessible to the Rev-01\n\n          -  NIHSS score is 8-30\n\n          -  Prior to new focal disabling neurologic deficit, mRS score was 0-2\n\n        Key Exclusion Criteria:\n\n          -  Acute intracranial hemorrhage\n\n          -  Mass effect or intracranial tumor\n\n          -  Extended early ischemic changes evidenced by CT or MRI\n\n          -  Administration of heparin within 48 hours preceding the onset of stroke and have an\n             elevated APTT or PTT above twice of the normal range for the laboratory at\n             presentation\n\n          -  Known bleeding diathesis of current use of oral anticoagulants (e.g., warfarin\n             sodium) with International Normalized Ration (INR) > 3\n\n          -  Platelet count < 30,000/mm3\n\n          -  Glucose < 50 mg/dL\n\n          -  Severe sustained hypertension (SBP > 185mmHG or DBP > 110mmHG) refractory to\n             pharmacological management\n\n          -  Life expectancy of less than 90 days\n\n          -  Pregnancy or females who are lactating\n\n          -  Current participation in an investigational drug or device study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895634", 
            "org_study_id": "Rev-01"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "Treatment arm patients have used Rev-01 at least once", 
            "intervention_name": "Rev-01", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ischemia", 
            "Stroke", 
            "Ischemic Stroke", 
            "Thrombectomy", 
            "Brain clot", 
            "Cerebrovascular disease", 
            "Recanalization", 
            "Revascularization", 
            "Clot Retriever", 
            "Neurovascular Intervention", 
            "Interventional Neuroradiology", 
            "neurovascular clinical trial"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kobe-city", 
                    "country": "Japan", 
                    "state": "Hyogo", 
                    "zip": "650-0046"
                }, 
                "name": "Kobe City Medical Center General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)", 
        "overall_contact": {
            "email": "kyagi1@its.jnj.com", 
            "last_name": "Kumiko Yagi", 
            "phone": "+81-3-4411-6789"
        }, 
        "overall_official": {
            "affiliation": "Kobe City Medical Center General Hospital", 
            "last_name": "Nobuyuki Sakai, M.D., D.M.Sc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients who have recanalization", 
            "safety_issue": "No", 
            "time_frame": "immediately post device procedural angiograms, after the device is removed and before final closure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895634"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Following neurological outcomes    - mRS score    - NIHSS score    - BI score", 
                "safety_issue": "No", 
                "time_frame": "90-day"
            }, 
            {
                "measure": "Proportion of patients with  ICH (symptomatic and asymptomatic)", 
                "safety_issue": "Yes", 
                "time_frame": "24-hour post procedure"
            }, 
            {
                "measure": "All cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "90 days post-procedure"
            }
        ], 
        "source": "Johnson & Johnson K.K. Medical Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johnson & Johnson K.K. Medical Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}